[Results of determining the sensitivity of hypernephroid cancer to cytostatic agents in vitro and clinically]. 1977

T G Terent'eva, and B P Matveev, and G A Martochkina, and E B Marinbakh

Sensitivity of the cells of 57 human hypernephromas was determined with respect to 8 drugs, i.e. tiodipin, fluorbenzotef, mithramycin, cyclophosphan, tiotef, rubomycin, 5-fluoruracyl and olivomycin with the help of the method of primary plasma cultures. Because of the changes introduced earlier into the estimative concentrations used in vitro, coincidence of the results of the sensitivity determined in vitro with the results obtained during the treatment of the same patients in clinics, significantly increased (up to 90 per cent).

UI MeSH Term Description Entries
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic

Related Publications

T G Terent'eva, and B P Matveev, and G A Martochkina, and E B Marinbakh
January 1972, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
T G Terent'eva, and B P Matveev, and G A Martochkina, and E B Marinbakh
January 1977, Cytobios,
T G Terent'eva, and B P Matveev, and G A Martochkina, and E B Marinbakh
May 2022, Biochemical pharmacology,
T G Terent'eva, and B P Matveev, and G A Martochkina, and E B Marinbakh
August 1976, The British journal of surgery,
T G Terent'eva, and B P Matveev, and G A Martochkina, and E B Marinbakh
February 1970, Zentralblatt fur Gynakologie,
T G Terent'eva, and B P Matveev, and G A Martochkina, and E B Marinbakh
January 1984, Neoplasma,
T G Terent'eva, and B P Matveev, and G A Martochkina, and E B Marinbakh
September 1978, The New England journal of medicine,
T G Terent'eva, and B P Matveev, and G A Martochkina, and E B Marinbakh
January 1975, Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology,
T G Terent'eva, and B P Matveev, and G A Martochkina, and E B Marinbakh
December 1980, Deutsche medizinische Wochenschrift (1946),
T G Terent'eva, and B P Matveev, and G A Martochkina, and E B Marinbakh
November 1976, Antibiotiki,
Copied contents to your clipboard!